Switzerland-based Roche has introduced new Elecsys Anti-Müllerian Hormone (AMH) fertility test, which will assess woman’s ovarian reserve.

During any day of the menstrual cycle, the AMH blood test can be performed, which offers better results compared to the follicle-stimulating hormone (FSH) and estradiol, according to the company.

Roche Diagnostics chief operating officer Roland Diggelmann said the Elecsys AMH test will enable healthcare professionals to incorporate AMH testing into routine clinical practice while getting more reliable results faster than conventional protocols and manual AMH assays.

"It is an important example of our focus on improving diagnostics in the area of women’s health," Diggelmann added.

The test will be available for sale in all markets accepting the CE mark in Europe, Latin America, Middle East, Africa and Asia, while it is currently not available in the US and Japan.

In the future, the company plans to use the Elecsys AMH assay in combination with the new human recombinant follicle-stimulating hormone (human rFSH) treatment, which is currently in phase III development at Ferring Pharmaceuticals.

Around 80 million people across the globe are facing fertility issues, noted WHO.